Blume-Jensen Peter sold ACRV

August 25, 2026 · Form 4 insider transaction

Blume-Jensen Peter sold 14,036 shares of Acrivon Therapeutics, Inc. at $2.21 per share, a transaction worth $31.0K. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Disposed (sell-side)
Shares
14,036
Price
$2.21
Total value
$31.0K
RoleOfficer, Director
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateAugust 25, 2026
Filing dateAugust 27, 2026
Shares owned after2,230,052
OwnershipDirect
10b5-1 planNo
AmendedNo

Footnotes

Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.; The price reported in Column 4 above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $2.17 to $2.25, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4.; These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.

View the original Form 4 on SEC EDGAR